Tags

Type your tag names separated by a space and hit enter

Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.

Abstract

Public concern on mental health has noticeably increased given the high prevalence of neuropsychiatric disorders. Cognition and emotionality are the most affected functions in neuropsychiatric disorders, i.e., anxiety disorders, depression, and schizophrenia. In this review, most relevant literature on the role of the endocannabinoid (eCB) system in neuropsychiatric disorders will be presented. Evidence from clinical and animal studies is provided for the participation of CB1 and CB2 receptors (CB1R and CB2R) in the above mentioned neuropsychiatric disorders. CBRs are crucial in some of the emotional and cognitive impairments reported, although more research is required to understand the specific role of the eCB system in neuropsychiatric disorders. Cannabidiol (CBD), the main non-psychotropic component of the Cannabis sativa plant, has shown therapeutic potential in several neuropsychiatric disorders. Although further studies are needed, recent studies indicate that CBD therapeutic effects may partially depend on facilitation of eCB-mediated neurotransmission. Last but not least, this review includes recent findings on the role of the eCB system in eating disorders. A deregulation of the eCB system has been proposed to be in the bases of several neuropsychiatric disorders, including eating disorders. Cannabis consumption has been related to the appearance of psychotic symptoms and schizophrenia. In contrast, the pharmacological manipulation of this eCB system has been proposed as a potential strategy for the treatment of anxiety disorders, depression, and anorexia nervosa. In conclusion, the eCB system plays a critical role in psychiatry; however, detrimental consequences of manipulating this endogenous system cannot be underestimated over the potential and promising perspectives of its therapeutic manipulation.

Authors+Show Affiliations

Departamento de Fisiología (Fisiología Animal II), Facultad de Ciencias Biológicas, Universidad Complutense de Madrid Madrid, Spain.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22007164

Citation

Marco, Eva M., et al. "Endocannabinoid System and Psychiatry: in Search of a Neurobiological Basis for Detrimental and Potential Therapeutic Effects." Frontiers in Behavioral Neuroscience, vol. 5, 2011, p. 63.
Marco EM, García-Gutiérrez MS, Bermúdez-Silva FJ, et al. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci. 2011;5:63.
Marco, E. M., García-Gutiérrez, M. S., Bermúdez-Silva, F. J., Moreira, F. A., Guimarães, F., Manzanares, J., & Viveros, M. P. (2011). Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Frontiers in Behavioral Neuroscience, 5, p. 63. doi:10.3389/fnbeh.2011.00063.
Marco EM, et al. Endocannabinoid System and Psychiatry: in Search of a Neurobiological Basis for Detrimental and Potential Therapeutic Effects. Front Behav Neurosci. 2011;5:63. PubMed PMID: 22007164.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. AU - Marco,Eva M, AU - García-Gutiérrez,María S, AU - Bermúdez-Silva,Francisco-Javier, AU - Moreira,Fabricio A, AU - Guimarães,Francisco, AU - Manzanares,Jorge, AU - Viveros,María-Paz, Y1 - 2011/10/05/ PY - 2011/06/11/received PY - 2011/09/09/accepted PY - 2011/10/19/entrez PY - 2011/10/19/pubmed PY - 2011/10/19/medline KW - anxiety KW - cannabidiol KW - cannabinoid receptor KW - cognition KW - depression KW - eating disorders KW - emotion KW - schizophrenia SP - 63 EP - 63 JF - Frontiers in behavioral neuroscience JO - Front Behav Neurosci VL - 5 N2 - Public concern on mental health has noticeably increased given the high prevalence of neuropsychiatric disorders. Cognition and emotionality are the most affected functions in neuropsychiatric disorders, i.e., anxiety disorders, depression, and schizophrenia. In this review, most relevant literature on the role of the endocannabinoid (eCB) system in neuropsychiatric disorders will be presented. Evidence from clinical and animal studies is provided for the participation of CB1 and CB2 receptors (CB1R and CB2R) in the above mentioned neuropsychiatric disorders. CBRs are crucial in some of the emotional and cognitive impairments reported, although more research is required to understand the specific role of the eCB system in neuropsychiatric disorders. Cannabidiol (CBD), the main non-psychotropic component of the Cannabis sativa plant, has shown therapeutic potential in several neuropsychiatric disorders. Although further studies are needed, recent studies indicate that CBD therapeutic effects may partially depend on facilitation of eCB-mediated neurotransmission. Last but not least, this review includes recent findings on the role of the eCB system in eating disorders. A deregulation of the eCB system has been proposed to be in the bases of several neuropsychiatric disorders, including eating disorders. Cannabis consumption has been related to the appearance of psychotic symptoms and schizophrenia. In contrast, the pharmacological manipulation of this eCB system has been proposed as a potential strategy for the treatment of anxiety disorders, depression, and anorexia nervosa. In conclusion, the eCB system plays a critical role in psychiatry; however, detrimental consequences of manipulating this endogenous system cannot be underestimated over the potential and promising perspectives of its therapeutic manipulation. SN - 1662-5153 UR - https://www.unboundmedicine.com/medline/citation/22007164/abstract/Endocannabinoid_system_and_ L2 - https://dx.doi.org/10.3389/fnbeh.2011.00063 DB - PRIME DP - Unbound Medicine ER -